Study guide

20.5 HIV Infection & Opportunistic Diseases

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

20.5 HIV Infection & Opportunistic Diseases

Key Takeaways Explain This Topic AI

Fourth-generation laboratory screening assays simultaneously detect HIV-1/2 antibodies and p24 antigen with a window period of 4 weeks; seroconversion illness manifests 2-6 weeks post-exposure as a glandular fever-like syndrome with intense viraemia.

Combined antiretroviral therapy (ART) is indicated universally upon diagnosis regardless of CD4 count; standard first-line therapy utilizes a triple-agent backbone of two NRTIs (e.g., tenofovir + emtricitabine) combined with an integrase strand transfer inhibitor (INSTI: dolutegravir or bictegravir).

Mandatory HLA-B*5701 genetic screening must precede abacavir initiation to prevent life-threatening multisystem hypersensitivity; tenofovir disoproxil fumarate (TDF) carries proximal renal tubulopathy and Fanconi syndrome risks, which are minimized by tenofovir alafenamide (TAF).

Pneumocystis jirovecii pneumonia (CD4 < 200/mcL) presents with exertional desaturation and elevated LDH; high-dose co-trimoxazole mandates adjunctive corticosteroids if room air PaO2 < 9.3 kPa (70 mmHg) or A-a gradient > 35 mmHg.

At CD4 < 100/mcL, cerebral toxoplasmosis (multiple ring-enhancing basal ganglia lesions) must be differentiated from primary CNS lymphoma (solitary, periventricular, EBV-driven), and cryptococcal meningitis requires induction with liposomal amphotericin B and flucytosine with aggressive therapeutic lumbar punctures to lower raised intracranial pressure.

Last updated: September 2026

Human Immunodeficiency Virus (HIV) medicine is a heavily examined component of the MRCP(UK) curriculum. Candidates must demonstrate deep understanding of contemporary diagnostic algorithms, viral kinetics, lifelong antiretroviral therapy (ART) regimens, pharmacogenomic safety markers, class-specific toxicities, and the clinical recognition and emergency management of opportunistic infections stratified by CD4 T-cell thresholds.

1. Virology, Diagnostic Testing & Clinical Course

HIV is an enveloped single-stranded RNA lentivirus belonging to the Retroviridae family. Viral surface glycoprotein gp120 binds to the host CD4 receptor on T-helper lymphocytes, monocytes, and macrophages. Consequential conformational changes allow gp120 to interact with chemokine co-receptors ( CCR5 in macrophage-tropic strains; CXCR4 in T-cell-tropic strains). Viral glycoprotein gp41 then mediates fusion of the viral envelope with the host cell membrane.

Modern Laboratory Diagnostics & The Diagnostic Window

4th Generation Laboratory Assay (The Gold Standard): Combined enzyme immunoassay (EIA) detecting both HIV-1 and HIV-2 antibodies (IgM and IgG) AND circulating free HIV-1 p24 antigen . The addition of p24 viral capsid protein shortens the diagnostic window period to approximately 4 weeks (28 days) post-exposure (compared to 6–12 weeks for antibody-only tests).

Confirmatory Algorithm: A reactive 4th generation screen mandates automated confirmatory testing using a secondary HIV-1/HIV-2 antibody differentiation immunoassay, followed by quantitative plasma HIV-1 RNA PCR .

Point-of-Care (POCT) Rapid Tests: Third-generation fingerprick capillary blood or oral fluid tests detect antibodies only; they have a prolonged window period of up to 12 weeks. Negative rapid tests following recent high-risk exposure require formal laboratory 4th generation testing at 4 weeks.

Primary HIV Seroconversion Illness

Occurs in 70 – 80 % 70\text{–}80\% 70 – 80% of newly infected individuals, typically 2 to 6 weeks following viral inoculation. It coincides with massive exponential viral replication, transient immune depletion, and high infectivity.

Clinical Syndrome: Resembles infectious mononucleosis (glandular fever-like): high fever, pharyngitis, non-tender generalized lymphadenopathy, myalgias, arthralgias, and a faint, non-pruritic erythematous maculopapular rash over the trunk and face. Mucocutaneous ulcerations (oral aphthous-like or genital ulcers) and aseptic meningoencephalitis are highly characteristic clues.

Diagnostic Caveat: In the earliest days of seroconversion, anti-HIV antibodies may still be undetectable (negative 3rd generation test), but p24 antigen and plasma HIV RNA PCR are astronomically elevated ( > 1 , 000 , 000 copies/mL > 1,000,000\text{ copies/mL} > 1 , 000 , 000 copies/mL ) .

  • 2. Antiretroviral Therapy (ART) Principles & Classes
  • Modern Treatment Mandates: Universal Immediate Initiation

Universal ART Initiation: British HIV Association (BHIVA) and WHO guidelines mandate initiation of ART in all individuals diagnosed with HIV, regardless of baseline CD4+ cell count or clinical stage .

Therapeutic Goals: Suppress viral replication to an undetectable plasma viral load ( < 50 copies/mL < 50\text{ copies/mL} < 50 copies/mL ) , restore functional CD4+ T-cell counts, halt disease progression, and eliminate horizontal transmission ( Undetectable = Untransmittable [U=U] ).

Standard First-Line Regimen (Triple Therapy Backbone):

Dual Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) : e.g., Tenofovir (TDF or TAF) + Emtricitabine (FTC), OR Abacavir (ABC) + Lamivudine (3TC).

PLUS a High-Barrier Third Agent: Preferably an Integrase Strand Transfer Inhibitor (INSTI) : Dolutegravir or Bictegravir .

  • Pharmacogenomic Safety & Antiretroviral Drug Classes [HIV Entry / Fusion]
  • │ (CCR5 Antagonists: Maraviroc; Fusion Inhibitor: Enfuvirtide)
  • ▼
  • [Reverse Transcription: Viral RNA → cDNA]
  • │ (NRTIs: Tenofovir, Abacavir, Emtricitabine, Lamivudine)
  • │ (NNRTIs: Efavirenz, Rilpivirine, Nevirapine)
  • ▼
  • [Proviral Integration into Host DNA]
  • │ (INSTIs: Dolutegravir, Bictegravir, Raltegravir)
  • ▼
  • [Viral Protein Cleavage & Virion Assembly]
  • │ (Protease Inhibitors: Darunavir, Atazanavir [+ Ritonavir / Cobicistat])
  • ▼
  • [Mature Infectious Virion]

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors (NRTIs):

Mechanism: Competitive inhibitors of HIV reverse transcriptase; lack a 3'-hydroxyl group, acting as obligate DNA chain terminators.

Class Toxicity: Inhibit host mitochondrial DNA polymerase-gamma, predisposing to lactic acidosis, hepatic steatosis , and peripheral lipoatrophy (most pronounced with historical agents: stavudine, didanosine, zidovudine).

Abacavir (ABC) & HLA-B*5701: Prescribing abacavir to patients carrying the major histocompatibility complex allele HLA-B*5701 triggers an acute, life-threatening multisystem hypersensitivity reaction (fever, rash, nausea, vomiting, dyspnoea). Mandatory genetic screening for HLA-B*5701 is legally required prior to prescribing abacavir ; if positive, abacavir is permanently contraindicated.

Tenofovir Disoproxil Fumarate (TDF) vs. Tenofovir Alafenamide (TAF): TDF delivers high systemic plasma tenofovir levels, which accumulate within renal proximal tubular cells, causing proximal renal tubular dysfunction (acquired Fanconi syndrome: hypophosphataemia, normoglycaemic glycosuria, proteinuria) and bone mineral density loss . TAF is a novel prodrug with targeted intracellular uptake into lymphocytes, yielding > 90 % > 90\% > 90% lower plasma concentrations and negligible renal/bone toxicity.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):

Mechanism: Non-competitive allosteric inhibitors binding an adjacent hydrophobic pocket of reverse transcriptase (e.g., Efavirenz, Rilpivirine, Nevirapine).

Toxicities: Efavirenz causes severe central nervous system neuropsychiatric adverse effects in > 50 % > 50\% > 50% (vivid nightmares, insomnia, depression, dizziness, daytime somnolence, depersonalization) and skin rash. Nevirapine causes severe fulminant hepatotoxicity and Stevens-Johnson syndrome.

Integrase Strand Transfer Inhibitors (INSTIs):

Mechanism: Bind catalytic divalent magnesium ions within the integrase active site, preventing strand transfer and incorporation of proviral cDNA into the host genome (e.g., Dolutegravir, Bictegravir, Raltegravir).

Profile: Exceptional viral suppression efficacy, high genetic barrier to resistance, minimal drug-drug interactions. Adverse effects include modest weight gain and rare insomnia.

Protease Inhibitors (PIs):

Mechanism: Inhibit HIV aspartyl protease, preventing the cleavage of Gag-Pol polyprotein precursors and rendering budding virions immature and non-infectious (e.g., Darunavir, Atazanavir).

Pharmacokinetic Boosting: Co-administered with low-dose ritonavir or cobicistat to inhibit cytochrome P450 CYP3A4, dramatically increasing PI plasma half-life.

Toxicities: Metabolic complications including dyslipidaemia, central visceral adiposity ('buffalo hump'), insulin resistance, and accelerated cardiovascular disease.

3. Opportunistic Infections Stratified by CD4 Thresholds

In untreated HIV infection, progressive depletion of CD4+ helper T-lymphocytes exposes the patient to opportunistic pathogens along predictable immunological thresholds.

CD4 Count Threshold Cardinal Opportunistic Pathogens Hallmark Clinical Presentation Definitive Diagnosis Acute Pharmacological Management

CD4 < 200 cells/ μ L < 200\text{ cells/}\mu\text{L} < 200 cells/ μ L Pneumocystis jirovecii Pneumonia (PCP) Subacute exertional dyspnoea, dry non-productive cough, fever; striking exercise-induced oxygen desaturation ; marked elevation of serum lactate dehydrogenase (LDH) Bilateral perihilar ground-glass opacities on HRCT; silver stain or immunofluorescence on induced sputum or bronchoalveolar lavage (BAL) High-dose co-trimoxazole ( 120 mg/kg/day 120\text{ mg/kg/day} 120 mg/kg/day in divided doses) for 21 days.; Add IV/oral corticosteroids if PaO 2 < 9.3 kPa \text{PaO}_2 < 9.3\text{ kPa} PaO 2 ​ < 9.3 kPa ( < 70 mmHg < 70\text{ mmHg} < 70 mmHg ) on room air.

CD4 < 200 cells/ μ L < 200\text{ cells/}\mu\text{L} < 200 cells/ μ L Candida albicans (Oesophageal) Severe odynophagia (retrosternal pain on swallowing), dysphagia, oral pseudomembranous candidiasis (thrush) Endoscopic visualization of creamy-white mucosal plaques; fungal scraping Oral fluconazole ( 200 – 400 mg 200\text{–}400\text{ mg} 200 – 400 mg daily for 14–21 days).

CD4 < 100 cells/ μ L < 100\text{ cells/}\mu\text{L} < 100 cells/ μ L Toxoplasma gondii Encephalitis Headache, confusion, fever, focal neurological deficits (hemiparesis, aphasia), seizures Brain MRI showing multiple ring-enhancing lesions with surrounding vasogenic oedema , predilection for basal ganglia; positive serum Toxoplasma IgG Pyrimethamine + Sulfadiazine + Folinic acid (Leucovorin) for 6 weeks.

CD4 < 100 cells/ μ L < 100\text{ cells/}\mu\text{L} < 100 cells/ μ L Cryptococcus neoformans Meningitis Subacute insidious headache, fever, malaise, cranial neuropathies; minimal neck stiffness; severely raised intracranial pressure Lumbar puncture: positive India ink preparation (encapsulated budding yeasts); Cryptococcal Antigen (CrAg) lateral flow assay > 98 % > 98\% > 98% sensitive Induction Therapy: IV Liposomal Amphotericin B ( 3 – 4 mg/kg/day 3\text{–}4\text{ mg/kg/day} 3 – 4 mg/kg/day ) PLUS oral Flucytosine ( 100 mg/kg/day 100\text{ mg/kg/day} 100 mg/kg/day in 4 divided doses) for ≥ 2 weeks \ge 2\text{ weeks} ≥ 2 weeks . Follow with fluconazole consolidation.

CD4 < 100 cells/ μ L < 100\text{ cells/}\mu\text{L} < 100 cells/ μ L Primary CNS Lymphoma (PCNSL) Progressive cognitive decline, focal deficits, seizures; non-Hodgkin large B-cell lymphoma driven by Epstein-Barr Virus (EBV) Brain MRI showing solitary (or few) thick, periventricular/subependymal ring-enhancing lesions ; positive EBV PCR in CSF High-dose IV methotrexate-based chemotherapy, whole-brain radiotherapy, immediate ART.

CD4 < 50 cells/ μ L < 50\text{ cells/}\mu\text{L} < 50 cells/ μ L Cytomegalovirus (CMV) Retinitis Painless blurred vision, floaters, scotomata; risk of retinal detachment and permanent blindness Fundoscopy: "pizza-pie" or "ketchup and scrambled eggs" fundus (confluent white retinal exudates with perivascular haemorrhages) Intravenous ganciclovir or oral valganciclovir ( 900 mg 900\text{ mg} 900 mg BD induction for 21 days, then OD maintenance).

CD4 < 50 cells/ μ L < 50\text{ cells/}\mu\text{L} < 50 cells/ μ L Mycobacterium avium Complex (MAC) Disseminated systemic illness: swinging fevers, drenching night sweats, severe wasting, profound anaemia, elevated alkaline phosphatase Automated liquid blood cultures (MGIT) for mycobacteria; mesenteric lymphadenopathy on CT Oral clarithromycin ( 500 mg 500\text{ mg} 500 mg BD) plus ethambutol ( 15 mg/kg 15\text{ mg/kg} 15 mg/kg OD).

CD4 < 50 cells/ μ L < 50\text{ cells/}\mu\text{L} < 50 cells/ μ L Progressive Multifocal Leukoencephalopathy (PML) Insidious subacute cognitive impairment, hemiparesis, visual field loss (homonymous hemianopia), limb ataxia; caused by JC polyomavirus Brain MRI: asymmetric, confluent non-enhancing subcortical white matter demyelination without mass effect ; positive CSF JC virus PCR No direct antiviral; immediate immune reconstitution via antiretroviral therapy (ART) .

  • 4. In-Depth Management of Major Opportunistic Conditions
  • Pneumocystis jirovecii Pneumonia (PCP)

Pathogen: Atypical, unicellular fungus with cholesterol rather than ergosterol in its plasma membrane (explaining intrinsic resistance to amphotericin B and azoles).

Clinical Presentation: Classically subacute (over 2–4 weeks): progressive exertional breathlessness, persistent non-productive cough, and fever. Auscultation is frequently unremarkable despite profound dyspnoea. Auscultation while walking demonstrates catastrophic, rapid exercise-induced arterial oxygen desaturation .

Biochemical & Radiographic Findings: Marked elevation of serum lactate dehydrogenase (LDH > 500 IU/L > 500\text{ IU/L} > 500 IU/L ) reflects diffuse alveolar injury. Chest radiograph demonstrates symmetrical bilateral perihilar bat-wing interstitial and alveolar infiltrates. HRCT reveals patchy or diffuse ground-glass attenuation with subpleural sparing.

Therapy & Systemic Corticosteroid Criteria:

First-line: High-dose oral or intravenous co-trimoxazole (trimethoprim 15 – 20 mg/kg/day 15\text{–}20\text{ mg/kg/day} 15 – 20 mg/kg/day plus sulfamethoxazole 75 – 100 mg/kg/day 75\text{–}100\text{ mg/kg/day} 75 – 100 mg/kg/day in 3–4 divided doses) for 21 days.

Adjunctive Corticosteroid Therapy: Dying fungal organisms release intense inflammatory antigens that trigger acute alveolar capillary injury, precipitating respiratory arrest 48–72 hours after commencing antibiotics. Systemic corticosteroids (oral prednisolone or IV methylprednisolone) are strictly indicated if:

Room air arterial PaO 2 < 9.3 kPa \text{PaO}_2 < 9.3\text{ kPa} PaO 2 ​ < 9.3 kPa ( < 70 mmHg < 70\text{ mmHg} < 70 mmHg ) , OR

Alveolar-arterial oxygen gradient ( A - a gradient A\text{-}a\ \text{gradient} A - a gradient ) ≥ 35 mmHg \ge 35\text{ mmHg} ≥ 35 mmHg .

Steroids must be administered prior to or concurrently with the first dose of co-trimoxazole (prednisolone 40 mg 40\text{ mg} 40 mg BD for 5 days, 40 mg 40\text{ mg} 40 mg OD for 5 days, then 20 mg 20\text{ mg} 20 mg OD for 11 days).

Cerebral Toxoplasmosis vs. Primary CNS Lymphoma

A classic MRCP diagnostic dilemma in patients with CD4 < 100 cells/ μ L < 100\text{ cells/}\mu\text{L} < 100 cells/ μ L :

Toxoplasma Encephalitis: Reactivation of encysted Toxoplasma gondii . MRI demonstrates multiple ring-enhancing lesions , classically located in the basal ganglia , thalamus, and corticomedullary junction, accompanied by prominent vasogenic oedema. Serum Toxoplasma IgG is positive in > 95 % > 95\% > 95% (negative IgG strongly points away from toxoplasmosis). First-line treatment: pyrimethamine, sulfadiazine, and folinic acid (leucovorin, added to prevent pyrimethamine-induced bone marrow suppression). Clinical and radiological improvement should be documented within 10 to 14 days.

Primary CNS Lymphoma (PCNSL): High-grade B-cell non-Hodgkin lymphoma driven by latent Epstein-Barr Virus (EBV) infection. MRI shows solitary (or fewer, larger) lesions , typically in a periventricular or subependymal distribution , demonstrating intense nodular or ring-like enhancement with mass effect. Lumbar puncture demonstrates positive EBV DNA by PCR in the CSF ( > 90 % > 90\% > 90% sensitivity and specificity) , confirming the diagnosis and precluding brain biopsy.

Cryptococcal Meningitis ( Cryptococcus neoformans )

Clinical Presentation: Encapsulated yeast acquired by inhalation of pigeon droppings. Disseminates to the central nervous system in profoundly immunosuppressed hosts (CD4 < 100 < 100 < 100 ). Presents indolently with persistent headache, malaise, low-grade fever, and vomiting, frequently with absent signs of meningism.

Severely Elevated Intracranial Pressure: Fungal capsular polysaccharide ( glucuronoxylomannan ) clogs arachnoid villi, producing severe non-communicating/communicating hydrocephalus with opening pressures > 30 – 40 cmH 2 O > 30\text{–}40\text{ cmH}_2\text{O} > 30 – 40 cmH 2 ​ O . Uncontrolled intracranial pressure is the principal cause of death and blindness.

Induction Therapy & ICP Management:

Induction: IV Liposomal Amphotericin B ( 3 – 4 mg/kg/day 3\text{–}4\text{ mg/kg/day} 3 – 4 mg/kg/day ) plus oral Flucytosine ( 100 mg/kg/day 100\text{ mg/kg/day} 100 mg/kg/day ) for 14 days (or high-dose single-dose liposomal amphotericin B 10 mg/kg 10\text{ mg/kg} 10 mg/kg stat with flucytosine/fluconazole as per the AMBITION-cm trial).

Daily Therapeutic Lumbar Punctures: Mandatory if opening pressure is > 25 cmH 2 O > 25\text{ cmH}_2\text{O} > 25 cmH 2 ​ O ; remove large volumes of CSF until pressure falls below 20 cmH 2 O 20\text{ cmH}_2\text{O} 20 cmH 2 ​ O or by 50 % 50\% 50% .

Timing of ART: ART initiation must be delayed for 2 to 4 weeks after starting antifungal therapy. Immediate ART triggers massive intracranial Immune Reconstitution Inflammatory Syndrome (IRIS) , with fatal cerebral herniation.

Prophylaxis Guidelines

Primary Prophylaxis against PCP: Recommended for all patients with a CD4 count < 200 cells/ μ L < 200\text{ cells/}\mu\text{L} < 200 cells/ μ L (or CD4 percentage < 14 % < 14\% < 14% ). First-line agent: oral co-trimoxazole ( 960 mg 960\text{ mg} 960 mg three times weekly or 480 mg 480\text{ mg} 480 mg once daily). Also confers cross-prophylaxis against Toxoplasma gondii . Discontinued once CD4 count remains > 200 cells/ μ L > 200\text{ cells/}\mu\text{L} > 200 cells/ μ L for ≥ 3 \ge 3 ≥ 3 consecutive months on suppressive ART.